- Home
- SUPV vs SLDB Comparison
SUPV vs SLDB Comparison
Compare SUPV & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPV
- SLDB
- Stock Information
- Founded
- SUPV 1887
- SLDB 2013
- Country
- SUPV Argentina
- SLDB United States
- Employees
- SUPV N/A
- SLDB N/A
- Industry
- SUPV Commercial Banks
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUPV Finance
- SLDB Health Care
- Exchange
- SUPV Nasdaq
- SLDB Nasdaq
- Market Cap
- SUPV 450.9M
- SLDB 464.1M
- IPO Year
- SUPV 2016
- SLDB 2018
- Fundamental
- Price
- SUPV $11.52
- SLDB $5.49
- Analyst Decision
- SUPV Hold
- SLDB Strong Buy
- Analyst Count
- SUPV 3
- SLDB 10
- Target Price
- SUPV $15.50
- SLDB $15.00
- AVG Volume (30 Days)
- SUPV 4.0M
- SLDB 1.0M
- Earning Date
- SUPV 11-24-2025
- SLDB 11-07-2025
- Dividend Yield
- SUPV 1.77%
- SLDB N/A
- EPS Growth
- SUPV N/A
- SLDB N/A
- EPS
- SUPV 0.09
- SLDB N/A
- Revenue
- SUPV $631,132,570.00
- SLDB N/A
- Revenue This Year
- SUPV $20.63
- SLDB N/A
- Revenue Next Year
- SUPV $22.47
- SLDB N/A
- P/E Ratio
- SUPV $24.27
- SLDB N/A
- Revenue Growth
- SUPV N/A
- SLDB N/A
- 52 Week Low
- SUPV $4.54
- SLDB $2.41
- 52 Week High
- SUPV $19.75
- SLDB $7.37
- Technical
- Relative Strength Index (RSI)
- SUPV 77.03
- SLDB 48.24
- Support Level
- SUPV $5.83
- SLDB $5.48
- Resistance Level
- SUPV $11.09
- SLDB $6.09
- Average True Range (ATR)
- SUPV 0.72
- SLDB 0.37
- MACD
- SUPV 0.63
- SLDB -0.03
- Stochastic Oscillator
- SUPV 93.65
- SLDB 28.26
About SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.